The perils of inhibiting deficient factors. (5th July 2018)

• Record Type: Journal Article
• Authors: Sayar, Z.; Speed, V.; Patel, J. P.; Patel, R. K.; Arya, R.
• Is Part Of: Journal of thrombosis and haemostasis. Volume 16:Number 8(2018)
• Page Start: 1535
• Page End: 1536
• Publication Date: 2018-07-05
• Subjects: coagulation -- factor X -- oral anticaogulants -- pharmacotherapeutics -- rivaroxaban; Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.14195
• Languages: English
• ISSNs: 1538-7933

Abstract

Abstract : Essentials Anticoagulation in patients with factor X deficiency is an evidence‐poor area. A patient with factor X deficiency was anticoagulated with warfarin followed by rivaroxaban. Warfarin may be a safer anticoagulant option than rivaroxaban in hereditary factor X deficiency. A baseline coagulation screen should be performed prior to commencement of anticoagulation. Summary: We report a case of a previously undiagnosed factor X deficiency in an 83‐year‐old man who had no previous bleeding history despite multiple hemostatic challenges. He was anticoagulated with warfarin for atrial fibrillation without bleeding complications; however, major hemorrhage occurred soon after a switch to rivaroxaban.